Morphic (MORF)
(Delayed Data from NSDQ)
$56.84 USD
+0.02 (0.04%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $56.86 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
MORF 56.84 +0.02(0.04%)
Will MORF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MORF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MORF
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
MORF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for July 9, 2024
What Makes Morphic (MORF) a New Buy Stock
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
Other News for MORF
Morphic Holding ticks higher after HSR waiting period for Eli Lilly deal expires
MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Morphic Holding (MORF) Receives a Hold from RBC Capital
MORF Stock Earnings: Morphic Holding Misses EPS for Q2 2024